{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04643366",
            "orgStudyIdInfo": {
                "id": "MCC-18-14260"
            },
            "secondaryIdInfos": [
                {
                    "id": "HM20020384",
                    "type": "OTHER",
                    "domain": "Virginia Commonwealth University"
                },
                {
                    "id": "NCI-2020-13796",
                    "type": "OTHER",
                    "domain": "NCI CTRP"
                }
            ],
            "organization": {
                "fullName": "Virginia Commonwealth University",
                "class": "OTHER"
            },
            "briefTitle": "Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer",
            "officialTitle": "Phase 2 Study of Total Neoadjuvant mFOLFOX and Short-Course Radiotherapy in Resectable Rectal Cancer",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "total-neoadjuvant-therapy-with-mfolfox-and-short-course-radiation-in-resectable-rectal-cancer"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-01",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-01-28",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2028-01-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2033-01-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2020-11-18",
            "studyFirstSubmitQcDate": "2020-11-18",
            "studyFirstPostDateStruct": {
                "date": "2020-11-25",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-01-30",
            "lastUpdatePostDateStruct": {
                "date": "2024-01-31",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Virginia Commonwealth University",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is phase 2 trial of neoadjuvant therapy and short-course radiotherapy in resectable rectal cancer.",
            "detailedDescription": "This trial involves 4 cycles of systemic chemotherapy followed by short-course RT with concurrent 5-FU neoadjuvant chemoradiotherapy (CRT) and subsequent consolidation with 4 cycles of systemic chemotherapy prior to surgery or, for those who achieve cCR, the option of non-operative active surveillance.Three-year disease free survival (DFS) defined as the percentage of patients alive without recurrence of disease at 3 years measured from the date of clinical complete response (cCR) or date of total mesorectal excision (TME) at surgery (whichever is earlier)."
        },
        "conditionsModule": {
            "conditions": [
                "Rectal Cancer"
            ],
            "keywords": [
                "Resectable",
                "Rectal"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 54,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Concurrent Chemotherapy/ Radiation Therapy",
                    "type": "EXPERIMENTAL",
                    "description": "5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) four 14-day cycles will be given before CRT starts. Pelvic Intensity-modulated radiation therapy (IMRT): 25 Gy in 5 fractions over 5 days + Continuous infusion 5-fluorouracil (5-FU) for 4 days (96 hours) followed by four 14-day cycles of (mFOLFOX6) to be given after CRT ends.",
                    "interventionNames": [
                        "Drug: Chemotherapy",
                        "Radiation: Radiation Therapy"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Chemotherapy",
                    "description": "Neoadjuvant chemotherapy with 2 months of combination oxaliplatin and 5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX)",
                    "armGroupLabels": [
                        "Concurrent Chemotherapy/ Radiation Therapy"
                    ]
                },
                {
                    "type": "RADIATION",
                    "name": "Radiation Therapy",
                    "description": "Pelvic Intensity-modulated radiation therapy (IMRT)",
                    "armGroupLabels": [
                        "Concurrent Chemotherapy/ Radiation Therapy"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Three-year disease free survival (DFS)",
                    "description": "The three-year disease free survival (DFS) defined as the number of patients alive without recurrence of disease at 3 years measured from the date of clinical complete response (cCR) or date of total mesorectal excision (TME) at surgery (whichever is earlier).",
                    "timeFrame": "3 years after end of treatment"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Pathologic complete response (pCR) rate",
                    "description": "The number of patients that achieve pathologic complete response(pCR)(defined as negative surgical margins and no evidence of residual viable tumor) at time of total mesorectal excision (TME).",
                    "timeFrame": "3 Years after end of treatment"
                },
                {
                    "measure": "Clinical complete response (cCR) following total neoadjuvant therapy (TNT) based on tumor response",
                    "description": "Determine the cCR using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), in patients evaluable for response",
                    "timeFrame": "3 Years after end of treatment"
                },
                {
                    "measure": "The number of Adverse events (AEs) per participant",
                    "description": "The number of Adverse events (AEs) per participant characterized and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE v. 5.0)",
                    "timeFrame": "39 Months"
                },
                {
                    "measure": "Progression (PFS) Rate",
                    "description": "PFS defined as the time from initiation of chemotherapy until date of progression",
                    "timeFrame": "3 Years after end of treatment"
                },
                {
                    "measure": "Overall Survival (OS) Rate",
                    "description": "OS defined as the time from initiation of chemotherapy until death by any cause.",
                    "timeFrame": "3 Years after end of treatment"
                },
                {
                    "measure": "Number of patients who do not require an ostomy at time of surgery",
                    "description": "After neoadjuvant therapy is complete patients will undergo assessment of disease status prior to determination of whether they will proceed to surgical resection or active surveillance",
                    "timeFrame": "116 Days"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Pathologic diagnosis of adenocarcinoma of the rectum (diagnosis by tissue biopsy) within 90 days prior to registration. At least a portion of the tumor must be located below the peritoneal reflection or begin within 12 cm of the anal verge on flexible endoscopy\n* Clinically staged (AJCC 8th ed.) T3-4 N0 M0 or T any N1-2 M0 based upon the following minimum diagnostic workup:\n\n  * Colonoscopy, unless patient presents with an obstructing lesion\n  * Within 30 days prior to registration:\n* History/physical examination\n* Imaging to exclude distant metastases: either contrast-enhanced CT of the chest, abdomen, and pelvis or whole-body PET-CT or MRI\n* Pelvic MRI (preferred) or transrectal ultrasound (TRUS) for T staging\n* ECOG Performance Status \u22641\n* Age \u2265 18 years\n* Adequate bone marrow function defined as follows:\n\n  * Absolute neutrophil count (ANC) \u2265 1,200 cells/mm3\n  * Platelets \u2265 100,000 cells/mm3\n  * Hemoglobin \u2265 8.0 g/dL (Note: The use of transfusion or other intervention to achieve Hgb \u22658.0 g/dL is acceptable.)\n* Adequate liver and renal function defined as follows:\n\n  * AST and alkaline phosphatase \\< 2.5 x upper limit of normal (ULN)\n  * Bilirubin \u2264 2.5 ULN\n  * Calculated creatinine clearance (CrCl) \\> 30 mL/min using Cockcroft-Gault formula as calculated by the standard Cockcroft-Gault equation using age, actual weight, creatinine, and gender\n* Must be deemed a candidate for curative resection by the surgical oncologist who will be performing the operation\n* Women of childbearing potential (WCBP) must have a negative serum pregnancy test performed within 7 days prior to the start of chemotherapy.\n* WCBP and men must agree to use a medically accepted form of birth control during the treatment and for 3 months following completion of chemotherapy.\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Prior RT that would result in overlap of RT fields with the planned study treatment\n* Clinically significant cardiac disease, including major cardiac dysfunction, that in the opinion of the treating medical oncologist would preclude them from receiving systemic therapy with 5-fluorouracil, leucovorin or oxaliplatin.\n* Serious (ie, \u2265 grade 3) uncontrolled infection\n* Pulmonary or respiratory condition that, in the opinion of the treating medical oncologist would preclude them from receiving systemic therapy with 5-fluorouracil, leucovorin or oxaliplatin.\n* Major surgery within 28 days of study enrollment (other than diverting colostomy)\n* History of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis) requiring significant intervention (eg, hospitalization, surgery, immunosuppressive medications) that would, in the opinion of the investigator, preclude study therapy\n* Prior known allergic reaction to 5-fluorouracil, leucovorin, or oxaliplatin\n* Known dipyrimidine dehydrogenase deficiency (DPD)\n* Any evidence of distant metastases (M1)\n* Pregnant or breast feeding\n* Medical, psychological, or social condition that, in the opinion of the investigator, may increase the patient's risk or limit the patient's adherence with study requirements",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Alison Ryan, NP",
                    "role": "CONTACT",
                    "phone": "804-628-1936",
                    "email": "ryanaa@vcu.edu"
                },
                {
                    "name": "Massey CTO Operations Managers",
                    "role": "CONTACT",
                    "email": "ctoclinops@vcu.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Khalid Matin, MD",
                    "affiliation": "Massey Cancer Center",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Virginia Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Richmond",
                    "state": "Virginia",
                    "zip": "23230",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Sue Moore, MSN, RN",
                            "role": "CONTACT",
                            "phone": "804-287-3000",
                            "phoneExt": "1261",
                            "email": "smoore@vacancer.com"
                        },
                        {
                            "name": "Purvi Shah, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.55376,
                        "lon": -77.46026
                    }
                },
                {
                    "facility": "Virginia Commonwealth University Massey Cancer Center",
                    "status": "RECRUITING",
                    "city": "Richmond",
                    "state": "Virginia",
                    "zip": "23298",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Massey SIIT Team",
                            "role": "CONTACT",
                            "phone": "804-628-9238",
                            "email": "Masseysiit@vcu.edu"
                        },
                        {
                            "name": "Massey Team Bravo",
                            "role": "CONTACT",
                            "email": "ctoclinops@vcu.edu"
                        },
                        {
                            "name": "Khalid Matin, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.55376,
                        "lon": -77.46026
                    }
                },
                {
                    "facility": "VCU Community Memorial Healthcenter",
                    "status": "RECRUITING",
                    "city": "South Hill",
                    "state": "Virginia",
                    "zip": "23970",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Massey SIIT Team",
                            "role": "CONTACT",
                            "email": "masseysiit@vcu.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 36.72653,
                        "lon": -78.12889
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000012004",
                    "term": "Rectal Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000015179",
                    "term": "Colorectal Neoplasms"
                },
                {
                    "id": "D000007414",
                    "term": "Intestinal Neoplasms"
                },
                {
                    "id": "D000005770",
                    "term": "Gastrointestinal Neoplasms"
                },
                {
                    "id": "D000004067",
                    "term": "Digestive System Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                },
                {
                    "id": "D000005767",
                    "term": "Gastrointestinal Diseases"
                },
                {
                    "id": "D000007410",
                    "term": "Intestinal Diseases"
                },
                {
                    "id": "D000012002",
                    "term": "Rectal Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M14846",
                    "name": "Rectal Neoplasms",
                    "asFound": "Rectal Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M17890",
                    "name": "Colorectal Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M10448",
                    "name": "Intestinal Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M7256",
                    "name": "Digestive System Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M8886",
                    "name": "Gastrointestinal Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10444",
                    "name": "Intestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14844",
                    "name": "Rectal Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M1674",
                    "name": "Oxaliplatin",
                    "relevance": "LOW"
                },
                {
                    "id": "M8600",
                    "name": "Fluorouracil",
                    "relevance": "LOW"
                },
                {
                    "id": "M6191",
                    "name": "Leucovorin",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Micro",
                    "name": "Micronutrients"
                }
            ]
        }
    },
    "hasResults": false
}